Cargando…

Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance

PLD-301, a phosphate prodrug of clopidogrel thiolactone discovered by Prelude Pharmaceuticals with the aim to overcome clopidogrel resistance, was evaluated for its in vivo inhibitory effect on ADP-induced platelet aggregation in rats. The potency of PLD-301 was similar to that of prasugrel, but muc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jingyu, Wang, Michael Zhiyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997949/ https://www.ncbi.nlm.nih.gov/pubmed/27594816 http://dx.doi.org/10.2174/1570180812666150730221941

Ejemplares similares

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
por: Neubauer, Horst, et al.
Publicado: (2011)

Postoperative Bleeding Risk for Oral Surgery under Continued Clopidogrel Antiplatelet Therapy
por: Gröbe, Alexander, et al.
Publicado: (2015)

Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice
por: Mullen, Liam, et al.
Publicado: (2021)

Strategies to Overcome Heparins’ Low Oral Bioavailability
por: Neves, Ana Rita, et al.
Publicado: (2016)

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment
por: Kang, Hyun Goo, et al.
Publicado: (2021)

Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed
por: Gosavi, Siddharth, et al.
Publicado: (2023)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
por: Hemlata,, et al.
Publicado: (2013)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers
por: Seo, Kwon-Duk, et al.
Publicado: (2014)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017)

Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers
por: Lee, Wonjae, et al.
Publicado: (2010)

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
por: Cirillo, Plinio, et al.
Publicado: (2020)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Analysis of Gastrointestinal Prophylaxis in Patients Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Morneau, Kathleen M., et al.
Publicado: (2014)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis
por: Krutilina, Raisa I., et al.
Publicado: (2022)

Masked Phenolic-Selenium Conjugates: Potent and Selective Antiproliferative Agents Overcoming P-gp Resistance
por: Begines, Paloma, et al.
Publicado: (2020)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial
por: Marcantoni, Emanuela, et al.
Publicado: (2022)

Impact of Grapefruit Juice on the Antiplatelet Activity of Loading and Maintenance Doses of Clopidogrel in Healthy Volunteers
por: Campbell, Jennifer A., et al.
Publicado: (2014)

Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea
por: Choi, Yoon Jin, et al.
Publicado: (2017)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Digital devices and systems with PLD applications /
por: Miller, Michael A.
Publicado: (1997)

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents
por: Li, Han-Xu, et al.
Publicado: (2023)

PLD1 and PLD2 differentially regulate the balance of macrophage polarization in inflammation and tissue injury
por: Hwang, Won Chan, et al.
Publicado: (2020)

Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors
por: Gavin, Amanda L., et al.
Publicado: (2021)

TMAO: a potential mediator of clopidogrel resistance
por: Ma, Ruisong, et al.
Publicado: (2021)

Role of sodium tungstate as a potential antiplatelet agent
por: Fernández-Ruiz, Rebeca, et al.
Publicado: (2015)

Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial
por: Zhang, Xiaoguang, et al.
Publicado: (2023)

Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel
por: Zhong, W‐P, et al.
Publicado: (2017)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl(T315I) inhibitor overcoming acquired imatinib resistance
por: Lu, Xiaoyun, et al.
Publicado: (2017)

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
por: Zhang, Weihe, et al.
Publicado: (2014)

PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing
por: Gavin, Amanda L., et al.
Publicado: (2018)

Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
por: Bassand, Jean-Pierre
Publicado: (2012)

Oral antiplatelet agent hypersensitivity and cross-reactivity managed by successful desensitisation
por: Chin, Nicholas, et al.
Publicado: (2015)

Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance
por: Petruzzella, Emanuele, et al.
Publicado: (2018)

Aspirin and Clopidogrel Resistance
por: Sztriha, Laszlo K., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_7g45q7lglovg86g688afrnq4rg